Fig. 5

AR promotes RASGRP3 transcription to mediate chemosensitivity. A Prediction of potential transcription factors in the RASGRP3 promoter region. B Expression of GATA-2, RXRα, FOXP3, and AR was assessed by Western blotting. C Western blotting to detect RASGRP3 expression in cell lysates after silencing AR with siRNA in LoVo-OxR (AC092894.1) and HCT116-OxR (AC092894.1) cells. D The effect of AR knockdown on apoptosis was examined by flow cytometry after treatment with oxaliplatin (5 μg/ml) for 48 h. E Statistical analysis of apoptosis rates. F The effect of AR knockdown on colony formation after 48-h treatment with oxaliplatin (5 μg/ml). G Counting and statistical analysis of the colony numbers. H RT-qPCR assays for RASGRP3 mRNA expression in LoVo-OxR (AC092894.1) and HCT116-OxR (AC092894.1) cells and their corresponding control vector cells. I Comparison of RASGRP3 promoter activity in AR knockdown cells with vector control cells. J Expression of AR in our cohort of CRC patients sensitive (n = 28) and resistant (n = 22) to oxaliplatin treatment